Corporate Updates

Medtronic

Medtronic, a leader among medical technology providers, has announced the United States Food and Drug Administration’s approval of the Medtronic Concerto/Virtuoso line of implantable cardiac devices. Market availability of these devices will follow in June 2006. The Concerto cardiac resynchronisation therapy-defibrillator (CRT-D) and Virtuoso implantable cardioverter defibrillator (ICD) are the first implantable cardiac devices available with Medtronic’s proprietary Conexus Wireless Telemetry, developed using the Medical Implant Communications Service (MICS, 402-405 MHz). Conexus Telemetry will enable automatic, wireless data transmission from the patient’s device to a home monitor. Medtronic Conexus Telemetry enables reliable communication between the patient’s implanted device and home monitor or clinician programmer at a range of two to five meters (approximately six to 16 feet).

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on


Most Popular

SUBSCRIBE OUR NEWSLETTER
200000+ Subscribers read it every day.
Subscribe Newsletter
To Top